Background: The purpose of the present study was to evaluate whether early postoperative D-dimer levels and certain pre-, intra-, and postoperative parameters can be used to predict venous thromboembolism (VTE) in gynecologic cancer patients.
introduction
Cancer is a widely accepted risk factor for venous thromboembolism (VTE) and, to a lesser extent, arterial thrombosis. This risk is attributed to factors such as the expression of prothrombotic factors by tumors, tumor compression of vessels, inflammatory host response to malignancies, immobility, surgery, indwelling central venous catheters, and certain antitumor therapies [1] . In surgical oncology patients, VTE is the biggest cause of death in the first 30 postoperative days [2] . VTE is also a common complication of gynecologic cancer surgery [3] . Moster reported that 90% of pulmonary thrombosis (PT) resulted from deep venous thrombosis (DVT), and that PT was observed in 15% of DVT cases [4] . Kearon [5] reported that in a large number of cases, VTE occurred between the intraoperative period and the first three postoperative days, and many of these patients resolved spontaneously (50% resolved within 72 h). The risk of progression of postoperative VTE appears to be greater if the initial thrombosis is large and if there are continuing risk factors for thrombosis. The risk of symptomatic VTE is generally highest within 2 weeks after surgery. It is therefore important to predict the occurrence of VTE as early as possible. A few studies have investigated the prediction of VTE after gynecologic cancer surgery [6, 7] . At present, there is no clinically useful information for predicting postoperative VTE in gynecological cancer patients.
D-dimer-a marker of the hypercoagulation stage-is a stable end product of fibrin degradation, and the levels of D-dimer increase as a result of fibrin formation and fibrinolysis. Plasma D-dimer measurement has been widely used for screening VTE. However, the time course of plasma Ddimer levels after surgery in gynecologic cancer patients has not been clarified. The purpose of the present study was to determine the postoperative plasma D-dimer levels in gynecologic cancer patients and to evaluate whether the early postoperative D-dimer levels can be considered a predictor of VTE. Furthermore, we investigated certain pre-, intra-, and postoperative parameters as risk factors for postoperative VTE. measurement of D-dimer levels and detection of VTE The plasma D-dimer level was measured serially before the operation and on postoperative days 0, 1, 3, 5, 7, 10, 14, and 21; measurements were also conducted after day 28. The latex photometric immunoassay system was used, and the amount of D-dimer was measured using LPIA-ACE D-D dimer II (Mitsubishi Chemical Medience Corporation, Tokyo, Japan) as the reagent. Interassay imprecision (coefficient of variation) is <10%. Although at our institution, <1.0 lg/ml is considered as the normal plasma D-dimer levels, the postoperative cut-off value for the second diagnostic tests was set at 10-15 lg/ml in accordance with our preliminary study. After the operation, primary screening for VTE was undertaken by meticulously evaluating the clinical signs and elevation of the plasma D-dimer level. For the clinical sign of VTE, we carefully examined the patients for leg swelling, tenderness along the distribution of deep veins, acute cardiovascular dysfunction, dyspnea, chest pain, and loss of consciousness. Patients whose plasma D-dimer concentration exceeded the cut-off values (10-15 lg/ml, especially >15 lg/ ml) and patients who showed clinical signs of VTE were subjected to computed tomography scanning of the chest to ankle region, using multidetector row computed tomography (MDCT) (Toshiba, Tokyo, Japan).
demographic data
Of 267 patients, 75 (28 with ovarian, 26 with endometrial, 19 with cervical, and 2 with vulvar cancer) underwent MDCT and were subjected to further investigations. Preoperative autologous blood collection was undertaken to minimize homologous blood transfusion in some cases of radical hysterectomy and/or para-aortic lymphadenectomy, and recombinant human erythropoietin (rHuEPO) was preferentially used to correct anemia associated with the collection of autologous blood. Thirty-six patients underwent preoperative autologous blood donation, and among them, 33 received rHuEPO. All the patients received general anesthesia. Calf-length external sequential compression devices were placed on both legs from the start of surgery in all patients; the use of these devices was continued after the operation. Forty-two patients received chemical anticoagulant therapy at the surgeon's discretion: low-dose unfractionated heparin (UFH) was administered s.c. at a dose of 5000 U two times a day for a median of 5 days (range 3-23 days) after surgery. Age, history, body mass index (BMI), hematological data, the results of biochemical and blood coagulation tests, type of surgery, intraoperative findings, and postoperative information were obtained from the patient charts.
statistical analyses
The chi-square test, Mann-Whitney U test, and logistic regression analysis were used to investigate the relationship between various variables and the occurrence of VTE. Probability values of <0.05 were considered statistically significant.
results
DVT and/or PT was detected in 21 (37.3%) of the 75 patients subjected to diagnostic MDCT on postoperative days 1-14 (median day 5) ( Table 1 ). Of these, PT was found in 11 patients (14.7%), 3 of whom showed clinical symptomatic signs of dyspnea or chest pain, neither of which was fatal. DVT was found in 17 patients, among whom 10 showed proximal DVT and 7 showed distal DVT. A substantial number of thrombi and PT were treated by anticoagulation therapy with parenteral UFH followed by oral warfarin. Vena cava filter insertion was required in the case of four patients.
postoperative plasma D-dimer levels
The plasma D-dimer value gradually increased, peaked on postoperative days 7-10, and then decreased ( Figure 1 ). The D-dimer value was significantly different between VTE-positive and VTE-negative patients on postoperative day 3 (median 7.1 lg/ml for VTE-positive patients and 4.7 lg/ml for VTEnegative patients, P = 0.009), day 5 (median 15.7 lg/ml for VTE-positive patients and 9.8 lg/ml for VTE-negative patients, P = 0.002), day 7 (median 19.5 lg/ml for VTE-positive patients and 12.8 lg/ml for VTE-negative patients, P = 0.023), and day 21 (median 4.1 lg/ml for VTE-positive patients and 7.9 lg/ml for VTE-negative patients, P = 0.041).
cut-off values for the D-dimer levels
The diagnostic performance of D-dimer values was assessed in patients with gynecologic malignancies. The cut-off values for D-dimer levels were chosen so as to achieve sensitivity and specificity values of at least >80% and >50%, respectively. The original article Annals of Oncology resulting cut-off values were 5 lg/ml (sensitivity 81.0% and specificity 57.4%) on day 3 and 10.5 lg/ml on day 5 (sensitivity 81.0% and specificity 61.1%). We found that 5 lg/ml was the optimal cut-off value on postoperative day 3 for predicting the occurrence of VTE as early as possible.
risk factors for postoperative VTE
To detect the occurrence of postoperative VTE early, it is preferable to carry out screening on postoperative days 1-3. We determined the predictors of VTE from among certain pre-, intra-, and postoperative parameters by using univariate and multivariate analyses. According to the results of univariate analysis, low BMI, the use of rHuEPO, non-O blood group, and the D-dimer value on postoperative day 3 were significant risk factors (Tables 2 and 3 ). None of the other parameters were found to be significant risk factors. Logistic regression multivariate analysis revealed that the D-dimer value on postoperative day 3, the use of rHuEPO, and non-O blood group were independent risk factors for predicting the occurrence of postoperative VTE (Table 4) .
discussion
In this study, we investigated the incidence and predictors of VTE, including asymptomatic VTE, in Japanese women with gynecologic cancer within 4 weeks after surgery. It has been reported that asymptomatic DVT is frequent, and it can lead to PT; it should be treated like symptomatic VTE [8] . However, contrary to therapy for proximal DVT, the therapeutic approach for distal DVT remains controversial. We used MDCT for detecting VTE because with MDCT, more detailed findings about DVT/PT can be obtained [9] . In the present study population, VTE was found in 8.2% of the patients before surgery and in 7.9% of the patients after surgery. Measurement of the plasma D-dimer level combined with assessment of the clinical pretest probability of thrombosis can be safely used to exclude the tentative diagnosis of DVT in cancer patients, eliminating the need for ultrasound imaging [10] . An The median is identified within a boxplot by a horizontal line inside the box. The lower edge of the whisker, the lower end of the box, the upper end of the box, and the upper edge of the whisker represent the 10th, 25th, 75th, and 90th percentiles, respectively. *P = 0.009, **P = 0.002, ***P = 0.02, ****P = 0.04. elevated D-dimer level is not a specific indicator of VTE; it is also observed in advancing age, during pregnancy, after surgery and trauma, in inflammatory states, infections, and some cancers [11] . False-positive results are common in cancer patients; thus, the specificity and positive predictive value of the assay is probably reduced in cancer patients. Satoh et al. [12] reported that if 1.5 lg/ml was used as the cut-off value for the D-dimer level (cut-off value for this method is 0.5 lg/ml) before surgery in ovarian cancer, VTE was detected with a sensitivity and specificity of 100% and 47.2%, respectively. The D-dimer level may be elevated after surgery. However, the kinetics of postoperative D-dimer levels remains unknown; therefore, the use of D-dimer measurement in surgical patients with suspected VTE is not very reliable [13] . We determined the postoperative plasma D-dimer levels in gynecologic cancer patients in order to evaluate whether the early postoperative D-dimer levels can used to predict VTE. We found that the plasma D-dimer value gradually increased, peaked on postoperative days 7-10, and then decreased. The D-dimer value was significantly higher in VTEpositive patients on postoperative days 3, 5, and 7. On the other hand, the D-dimer value was significantly lower in VTEpositive patients on postoperative day 21. This can be explained by the fact that VTE-positive patients were treated by parenteral UFH. We determined the optimal cut-off value for the D-dimer as 5 lg/ml on postoperative day 3. Furthermore, we demonstrated that the high plasma D-dimer level on postoperative day 3 is an independent risk factor for postoperative VTE in gynecologic cancer patients. Consistent with the results of our study, Yoshitaka et al. [14] reported that the D-dimer levels on postoperative day 3 was an independent risk factor for VTE in patients who underwent total knee arthroplasty. Further studies are required to determine the usefulness of D-dimer measurement as a diagnostic approach for postoperative VTE.
The ABO blood group system involving red blood cell membrane antigens was first established by Landsteiner in 1900. The ABO blood group system has been reported to be associated with blood coagulation. Individuals with non-O blood groups are at a significantly increased risk of arterial thromboembolic disease and VTE [15, 16] . According to the ABO blood group system, the blood group is determined by the plasma levels of two coagulation glycoproteins-von Willebrand factor (vWF) and Factor VIII (FVIII). vWF and FVIII are found in circulation in normal plasma as a noncovalent complex and both play crucial roles in normal hemostasis. Compared with non-O group individuals, those with blood group O show significantly reduced plasma vWF and FVIII levels; this explains their reduced levels in individuals with clinical thrombosis [17] . Streiff et al. [18] reported that for patients with malignant glioma, the hazard ratios for thrombosis were 2.7 and 9.4 for patients with blood groups A and AB, respectively, compared with patients with blood group O. Here, for the first time, non-O blood group has been demonstrated to be an independent risk factor for postoperative VTE in gynecologic cancer patients. The ABO blood type is routinely determined before surgery, and it may be used for decision making with regard to VTE prophylaxis.
Abu-Rustum et al. [19] reported that postoperative blood product transfusions, particularly fresh frozen plasma, were associated with increased risk of DVT and PT in women with stage IIIc-IV adnexal/peritoneal cancer. At our institution, preoperative autologous blood collection is undertaken to minimize homologous blood transfusion in cases of radical hysterectomy and/or para-aortic lymphadenectomy, and rHuEPO is preferentially used to correct anemia associated with the collection of autologous blood. rHuEPO is a biosynthetic form of erythropoietin; its biochemical structure and biological effects are similar to those of erythropoietin [20] . Therefore, at our institution, it is common practice to carry out autologous blood donation with the aid of rHuEPO, at the time of presentation. Analysis of the rHuEPO safety profile in patients treated before they underwent orthopedic surgery showed that the use of this hormone does not increase the risk of thromboembolic events [21] . However, we demonstrated that the use of rHuEPO is an independent risk factor for the development of VTE after surgery for gynecologic cancer.
A meta-analysis revealed that the administration of erythropoiesis-stimulating agent (ESA) to cancer patients is associated with a 1.57-fold increased risk of VTE and a 1.10-fold increased risk of mortality [22] . However, additional research on ESA safety will be required to confirm these values. C-reactive protein (CRP) is a downstream marker of inflammation and is considered a predictor of cardiovascular events and mortality [23] . A prospective study on 507 cancer patients reported that elevated CRP was associated with the development of VTE [24] . Moreover, some studies demonstrated that elevated platelet (PLT) counts were associated with VTE in cancer patients [25] . However, in our study, CRP and PLT counts were not associated with VTE.
Martino et al. [26] reported that patients with gynecological cancer undergoing major abdominal surgery and using pneumatic compression for thromboembolic prophylaxis had a 14-fold greater odds of developing a pulmonary embolism compared with patients with benign disease. In the present study, we found that even though UFH was administered two times daily for only 5 days, there was no difference between thromboprophylaxis with UFH and no chemical anticoagulant therapy in terms of the development of VTE. This could be partly attributed to the fact that patients who had received UFH had undergone more aggressive operation, although not statistically significant (data not shown). It has been reported that low-molecular-weight heparin (LMWH) was superior to UFH, when UFH was administered two times a day [27] . Patients with ovarian cancer have been reported to show a later onset and particularly high incidence of VTE after the seventh postoperative day [28, 29] . The American College of Chest Physicians recommends that thromboprophylaxis with LMWH be continued for up to 28 days in select high-risk gynecology patients, including those who have undergone major cancer surgery [30] . Currently, at our institute, prophylaxis with LMWH is continued for at least 10-14 days after operation.
We have listed the limitations to our study here. This was a single-institution analysis of cervical, endometrial, ovarian, and vulvar cancers. We chose MDCT as the diagnostic test for several reasons: its availability, ease of performance, and acceptable levels of sensitivity and specificity for detecting VTE. However, MDCT was carried out only in patients with symptoms of VTE or D-dimer levels >10-15 lg/ml at any time point because of which it is likely that the incidence of VTE was underestimated.
Our current findings proved that high plasma D-dimer value on postoperative day 3 is an independent risk factor for postoperative VTE in gynecologic cancer patients. Furthermore, we demonstrated through multivariate analysis that the use of rHuEPO and non-O blood group were also independent risk factors for postoperative VTE. 
